| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neurofibromatosis 2 | 62 | 2023 | 380 | 14.550 |
Why?
|
| Neurofibromatoses | 54 | 2023 | 299 | 13.840 |
Why?
|
| Neurofibromatosis 1 | 55 | 2024 | 570 | 11.170 |
Why?
|
| Neurilemmoma | 48 | 2023 | 547 | 10.860 |
Why?
|
| Neuroma, Acoustic | 25 | 2023 | 451 | 5.300 |
Why?
|
| Skin Neoplasms | 42 | 2024 | 5692 | 3.720 |
Why?
|
| Hearing Loss | 14 | 2023 | 765 | 2.750 |
Why?
|
| Neurofibroma | 10 | 2024 | 106 | 2.300 |
Why?
|
| Nerve Sheath Neoplasms | 6 | 2020 | 191 | 1.780 |
Why?
|
| Neurofibroma, Plexiform | 8 | 2022 | 71 | 1.740 |
Why?
|
| Meningeal Neoplasms | 15 | 2023 | 1241 | 1.660 |
Why?
|
| Angiogenesis Inhibitors | 12 | 2019 | 2038 | 1.560 |
Why?
|
| von Hippel-Lindau Disease | 3 | 2020 | 152 | 1.440 |
Why?
|
| Neurofibromin 2 | 14 | 2023 | 267 | 1.440 |
Why?
|
| Meningioma | 14 | 2023 | 1209 | 1.360 |
Why?
|
| Clinical Trials as Topic | 18 | 2023 | 7914 | 1.170 |
Why?
|
| Brain Neoplasms | 21 | 2021 | 8861 | 1.150 |
Why?
|
| Nervous System Neoplasms | 3 | 2018 | 91 | 1.020 |
Why?
|
| Quinazolines | 9 | 2015 | 1356 | 1.010 |
Why?
|
| Rare Diseases | 7 | 2022 | 553 | 0.980 |
Why?
|
| Whole Body Imaging | 8 | 2020 | 280 | 0.950 |
Why?
|
| Quality of Life | 19 | 2023 | 12802 | 0.900 |
Why?
|
| Tuberous Sclerosis | 3 | 2020 | 1029 | 0.890 |
Why?
|
| Chromosomal Proteins, Non-Histone | 4 | 2013 | 735 | 0.820 |
Why?
|
| Lymphoma | 6 | 2023 | 1877 | 0.710 |
Why?
|
| Maternal Mortality | 2 | 2013 | 310 | 0.700 |
Why?
|
| Mind-Body Therapies | 3 | 2019 | 247 | 0.680 |
Why?
|
| Tumor Burden | 8 | 2022 | 1915 | 0.680 |
Why?
|
| Peripheral Nervous System Neoplasms | 3 | 2017 | 122 | 0.680 |
Why?
|
| Glioblastoma | 12 | 2021 | 3481 | 0.640 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2020 | 241 | 0.630 |
Why?
|
| Central Nervous System Neoplasms | 5 | 2023 | 895 | 0.610 |
Why?
|
| Humans | 193 | 2024 | 744366 | 0.600 |
Why?
|
| Consensus | 5 | 2023 | 2960 | 0.590 |
Why?
|
| Spinal Cord Neoplasms | 4 | 2015 | 281 | 0.580 |
Why?
|
| Telemedicine | 6 | 2021 | 2872 | 0.570 |
Why?
|
| Adult | 85 | 2023 | 214052 | 0.560 |
Why?
|
| Psychotherapy, Group | 2 | 2019 | 406 | 0.560 |
Why?
|
| Oscillometry | 1 | 2016 | 147 | 0.550 |
Why?
|
| Pregnancy Complications | 3 | 2015 | 2861 | 0.540 |
Why?
|
| Pregnancy Outcome | 3 | 2015 | 2795 | 0.540 |
Why?
|
| Young Adult | 38 | 2023 | 56429 | 0.510 |
Why?
|
| Treatment Outcome | 29 | 2023 | 63107 | 0.510 |
Why?
|
| Ependymoma | 3 | 2015 | 334 | 0.490 |
Why?
|
| Germ-Line Mutation | 5 | 2020 | 1788 | 0.490 |
Why?
|
| Hearing Tests | 2 | 2019 | 122 | 0.480 |
Why?
|
| Facial Nerve Diseases | 1 | 2013 | 50 | 0.460 |
Why?
|
| Magnetic Resonance Imaging | 34 | 2022 | 35425 | 0.460 |
Why?
|
| Spirometry | 1 | 2016 | 865 | 0.450 |
Why?
|
| Adolescent | 44 | 2023 | 85779 | 0.440 |
Why?
|
| Vascular Endothelial Growth Factor A | 6 | 2017 | 3511 | 0.430 |
Why?
|
| Preimplantation Diagnosis | 1 | 2014 | 151 | 0.430 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2014 | 2016 | 0.420 |
Why?
|
| Lymphatic Diseases | 1 | 2014 | 323 | 0.420 |
Why?
|
| Antineoplastic Agents | 14 | 2021 | 13693 | 0.420 |
Why?
|
| S100 Proteins | 1 | 2012 | 259 | 0.410 |
Why?
|
| Osteoarthritis, Knee | 1 | 2022 | 1222 | 0.410 |
Why?
|
| Middle Aged | 66 | 2022 | 213390 | 0.400 |
Why?
|
| Male | 88 | 2023 | 350115 | 0.400 |
Why?
|
| Enkephalins | 3 | 2001 | 154 | 0.380 |
Why?
|
| Female | 85 | 2023 | 380193 | 0.380 |
Why?
|
| Relaxation Therapy | 3 | 2023 | 178 | 0.370 |
Why?
|
| Transcription Factors | 7 | 2020 | 12207 | 0.370 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2012 | 629 | 0.360 |
Why?
|
| Enkephalin, Methionine | 3 | 2001 | 26 | 0.360 |
Why?
|
| TOR Serine-Threonine Kinases | 3 | 2020 | 2110 | 0.360 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2012 | 255 | 0.350 |
Why?
|
| DNA-Binding Proteins | 4 | 2013 | 9647 | 0.350 |
Why?
|
| Polysomnography | 1 | 2016 | 1776 | 0.350 |
Why?
|
| Nerve Growth Factors | 1 | 2012 | 574 | 0.350 |
Why?
|
| Medical Oncology | 3 | 2022 | 2267 | 0.350 |
Why?
|
| Affective Symptoms | 1 | 2012 | 407 | 0.350 |
Why?
|
| Genetic Association Studies | 5 | 2020 | 2703 | 0.340 |
Why?
|
| Videoconferencing | 4 | 2019 | 195 | 0.340 |
Why?
|
| Neoplasm Recurrence, Local | 10 | 2021 | 9240 | 0.330 |
Why?
|
| Child | 30 | 2024 | 77709 | 0.330 |
Why?
|
| Spinal Nerves | 1 | 2009 | 86 | 0.330 |
Why?
|
| Cerebrovascular Disorders | 1 | 2015 | 1504 | 0.330 |
Why?
|
| Follow-Up Studies | 20 | 2023 | 39052 | 0.320 |
Why?
|
| Cranial Nerves | 1 | 2009 | 101 | 0.320 |
Why?
|
| Ambulatory Care | 2 | 2018 | 2708 | 0.320 |
Why?
|
| Multiprotein Complexes | 2 | 2014 | 1120 | 0.320 |
Why?
|
| Methotrexate | 3 | 2023 | 1728 | 0.310 |
Why?
|
| Ethanol | 3 | 2001 | 1342 | 0.310 |
Why?
|
| Herpes Zoster Oticus | 1 | 2007 | 8 | 0.310 |
Why?
|
| Ear Neoplasms | 1 | 2008 | 117 | 0.310 |
Why?
|
| Obstetric Labor, Premature | 3 | 2015 | 279 | 0.300 |
Why?
|
| ras Proteins | 3 | 2019 | 1060 | 0.300 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2009 | 1097 | 0.290 |
Why?
|
| Cafe-au-Lait Spots | 2 | 2021 | 18 | 0.290 |
Why?
|
| Resilience, Psychological | 3 | 2020 | 677 | 0.280 |
Why?
|
| Positron-Emission Tomography | 4 | 2019 | 6234 | 0.280 |
Why?
|
| Single-Blind Method | 6 | 2023 | 1590 | 0.280 |
Why?
|
| Disease Progression | 8 | 2017 | 13286 | 0.280 |
Why?
|
| Interleukin-1 | 4 | 2000 | 1263 | 0.270 |
Why?
|
| Molecular Targeted Therapy | 3 | 2019 | 2725 | 0.270 |
Why?
|
| Astrocytoma | 1 | 2010 | 790 | 0.270 |
Why?
|
| Population Surveillance | 2 | 2016 | 2616 | 0.270 |
Why?
|
| Pain Measurement | 4 | 2022 | 3420 | 0.270 |
Why?
|
| Research | 1 | 2014 | 1999 | 0.270 |
Why?
|
| Audiometry, Pure-Tone | 3 | 2012 | 204 | 0.270 |
Why?
|
| Hearing Loss, Sensorineural | 2 | 2010 | 770 | 0.260 |
Why?
|
| Attitude to Health | 2 | 2008 | 2052 | 0.260 |
Why?
|
| Nervous System | 1 | 2009 | 554 | 0.260 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2004 | 1381 | 0.260 |
Why?
|
| Viral Envelope Proteins | 3 | 1996 | 636 | 0.260 |
Why?
|
| Methionine | 1 | 2007 | 590 | 0.250 |
Why?
|
| Spinal Neoplasms | 1 | 2012 | 760 | 0.250 |
Why?
|
| Brain Diseases | 1 | 2014 | 1563 | 0.250 |
Why?
|
| Aged | 36 | 2022 | 163288 | 0.250 |
Why?
|
| Genes, Neurofibromatosis 1 | 3 | 2021 | 79 | 0.250 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2022 | 10943 | 0.250 |
Why?
|
| Cranial Nerve Neoplasms | 1 | 2005 | 129 | 0.250 |
Why?
|
| Mitogen-Activated Protein Kinases | 3 | 2020 | 1284 | 0.250 |
Why?
|
| Rabies Vaccines | 2 | 1996 | 31 | 0.250 |
Why?
|
| Antibodies, Monoclonal | 3 | 2010 | 9274 | 0.250 |
Why?
|
| Blood-Brain Barrier | 4 | 2000 | 1019 | 0.240 |
Why?
|
| Substance Withdrawal Syndrome | 2 | 2001 | 632 | 0.240 |
Why?
|
| Hypesthesia | 1 | 2005 | 109 | 0.240 |
Why?
|
| Prospective Studies | 17 | 2023 | 53290 | 0.240 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 3 | 2023 | 647 | 0.240 |
Why?
|
| Retrospective Studies | 22 | 2023 | 77460 | 0.240 |
Why?
|
| Disease Models, Animal | 6 | 2021 | 18034 | 0.240 |
Why?
|
| Cochlear Implantation | 1 | 2008 | 310 | 0.230 |
Why?
|
| Genes, Neurofibromatosis 2 | 3 | 2008 | 124 | 0.230 |
Why?
|
| Seminoma | 1 | 2005 | 139 | 0.230 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2005 | 151 | 0.230 |
Why?
|
| Radiation Injuries | 1 | 2010 | 1180 | 0.220 |
Why?
|
| Hearing | 4 | 2022 | 482 | 0.220 |
Why?
|
| Patient Selection | 2 | 2021 | 4216 | 0.220 |
Why?
|
| Stress, Psychological | 2 | 2015 | 4245 | 0.220 |
Why?
|
| Lymph Nodes | 1 | 2014 | 3476 | 0.210 |
Why?
|
| Neuroma | 1 | 2023 | 103 | 0.210 |
Why?
|
| Survival Rate | 7 | 2019 | 12788 | 0.210 |
Why?
|
| Demyelinating Diseases | 1 | 2005 | 354 | 0.210 |
Why?
|
| Hamartoma | 1 | 2024 | 238 | 0.210 |
Why?
|
| Anxiety | 1 | 2016 | 4293 | 0.200 |
Why?
|
| Protein Kinase Inhibitors | 8 | 2023 | 5534 | 0.200 |
Why?
|
| Connective Tissue Diseases | 2 | 2021 | 264 | 0.200 |
Why?
|
| MSH Release-Inhibiting Hormone | 1 | 2001 | 9 | 0.200 |
Why?
|
| Vaccines, Synthetic | 2 | 1996 | 634 | 0.200 |
Why?
|
| Drug Administration Schedule | 3 | 2016 | 4933 | 0.200 |
Why?
|
| Arthrogryposis | 1 | 2022 | 72 | 0.200 |
Why?
|
| Fibroblast Growth Factor 7 | 1 | 2021 | 61 | 0.190 |
Why?
|
| Diphenylamine | 1 | 2021 | 50 | 0.190 |
Why?
|
| Isometric Contraction | 1 | 2021 | 143 | 0.190 |
Why?
|
| Blood-Testis Barrier | 1 | 2000 | 11 | 0.190 |
Why?
|
| Health Services Accessibility | 1 | 2018 | 5135 | 0.190 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2014 | 1524 | 0.190 |
Why?
|
| Pseudarthrosis | 1 | 2021 | 59 | 0.190 |
Why?
|
| Genetic Diseases, Inborn | 2 | 2016 | 587 | 0.190 |
Why?
|
| Glycoproteins | 3 | 1996 | 2266 | 0.190 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2004 | 640 | 0.190 |
Why?
|
| Cesarean Section | 3 | 2015 | 1365 | 0.190 |
Why?
|
| Tinnitus | 1 | 2023 | 195 | 0.180 |
Why?
|
| Organophosphorus Compounds | 1 | 2021 | 215 | 0.180 |
Why?
|
| Benzamides | 3 | 2021 | 1379 | 0.180 |
Why?
|
| Antigens, Viral | 2 | 1996 | 1035 | 0.180 |
Why?
|
| Central Nervous System Depressants | 1 | 2001 | 167 | 0.180 |
Why?
|
| Neuregulin-1 | 1 | 2020 | 142 | 0.180 |
Why?
|
| Mutation, Missense | 3 | 2017 | 2566 | 0.180 |
Why?
|
| Hydrazines | 1 | 2021 | 226 | 0.180 |
Why?
|
| Autocrine Communication | 1 | 2020 | 171 | 0.180 |
Why?
|
| Receptor, erbB-3 | 1 | 2020 | 142 | 0.180 |
Why?
|
| Protein Precursors | 3 | 2001 | 1154 | 0.180 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2023 | 290 | 0.180 |
Why?
|
| Cerebellar Neoplasms | 1 | 2005 | 587 | 0.170 |
Why?
|
| Muscle Weakness | 2 | 2021 | 413 | 0.170 |
Why?
|
| Hospitalization | 4 | 2015 | 10259 | 0.170 |
Why?
|
| Radiosurgery | 3 | 2022 | 1329 | 0.170 |
Why?
|
| Neovascularization, Pathologic | 4 | 2017 | 2638 | 0.170 |
Why?
|
| Prognosis | 13 | 2021 | 29060 | 0.170 |
Why?
|
| Depression | 2 | 2016 | 7759 | 0.170 |
Why?
|
| International Classification of Diseases | 2 | 2015 | 867 | 0.170 |
Why?
|
| Medicine, Traditional | 1 | 1999 | 91 | 0.170 |
Why?
|
| Cerebellopontine Angle | 1 | 2019 | 55 | 0.170 |
Why?
|
| Bone Morphogenetic Protein 2 | 1 | 2021 | 350 | 0.170 |
Why?
|
| Fetal Growth Retardation | 2 | 2013 | 570 | 0.160 |
Why?
|
| Receptors, Eph Family | 1 | 2018 | 44 | 0.160 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2009 | 4042 | 0.160 |
Why?
|
| Neurology | 2 | 2021 | 763 | 0.160 |
Why?
|
| Testicular Neoplasms | 1 | 2005 | 806 | 0.160 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2020 | 390 | 0.160 |
Why?
|
| Pain | 6 | 2023 | 4988 | 0.160 |
Why?
|
| Brain Death | 1 | 2001 | 348 | 0.160 |
Why?
|
| Spinal Injuries | 1 | 2001 | 301 | 0.160 |
Why?
|
| Organizations, Nonprofit | 1 | 2018 | 104 | 0.160 |
Why?
|
| Bone and Bones | 1 | 2009 | 2576 | 0.150 |
Why?
|
| Anilides | 1 | 2021 | 408 | 0.150 |
Why?
|
| Immunohistochemistry | 5 | 2015 | 11366 | 0.150 |
Why?
|
| Salvage Therapy | 1 | 2004 | 1275 | 0.150 |
Why?
|
| Tumor Microenvironment | 4 | 2021 | 3590 | 0.150 |
Why?
|
| Adjuvants, Immunologic | 1 | 2003 | 1000 | 0.150 |
Why?
|
| Cohort Studies | 10 | 2020 | 40559 | 0.150 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2017 | 3326 | 0.150 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2003 | 685 | 0.150 |
Why?
|
| Muscle Strength | 1 | 2021 | 592 | 0.150 |
Why?
|
| Seizures | 3 | 2001 | 2859 | 0.150 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2023 | 1271 | 0.140 |
Why?
|
| Avipoxvirus | 1 | 1996 | 4 | 0.140 |
Why?
|
| Patient Satisfaction | 2 | 2021 | 3395 | 0.140 |
Why?
|
| Neurofibromin 1 | 1 | 2017 | 196 | 0.140 |
Why?
|
| Animals | 28 | 2023 | 168768 | 0.140 |
Why?
|
| Boston | 4 | 2015 | 9312 | 0.140 |
Why?
|
| Pyrimidines | 4 | 2021 | 2943 | 0.140 |
Why?
|
| Attitude | 1 | 2021 | 776 | 0.140 |
Why?
|
| Codon | 1 | 2017 | 611 | 0.130 |
Why?
|
| Triazoles | 1 | 2021 | 908 | 0.130 |
Why?
|
| Capillary Permeability | 1 | 2019 | 798 | 0.130 |
Why?
|
| Anesthesia, Local | 1 | 1998 | 275 | 0.130 |
Why?
|
| Dacarbazine | 3 | 2013 | 566 | 0.130 |
Why?
|
| Cytomegalovirus | 2 | 1990 | 733 | 0.130 |
Why?
|
| Analgesics | 1 | 2022 | 1040 | 0.130 |
Why?
|
| Neuropeptides | 2 | 2001 | 942 | 0.130 |
Why?
|
| Health Literacy | 2 | 2017 | 414 | 0.130 |
Why?
|
| Disease-Free Survival | 6 | 2015 | 6896 | 0.130 |
Why?
|
| Skin | 1 | 2009 | 4372 | 0.130 |
Why?
|
| Feasibility Studies | 4 | 2019 | 5077 | 0.130 |
Why?
|
| Cervical Vertebrae | 1 | 2001 | 976 | 0.130 |
Why?
|
| Deafness | 1 | 2019 | 458 | 0.130 |
Why?
|
| Attitude of Health Personnel | 1 | 2008 | 3841 | 0.120 |
Why?
|
| Pyridines | 2 | 2021 | 2825 | 0.120 |
Why?
|
| Pre-Eclampsia | 2 | 2015 | 1200 | 0.120 |
Why?
|
| Relaxation | 1 | 2014 | 50 | 0.120 |
Why?
|
| Diagnostic Errors | 1 | 2001 | 1257 | 0.120 |
Why?
|
| Compassionate Use Trials | 1 | 2014 | 46 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2018 | 578 | 0.120 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 3 | 2015 | 547 | 0.120 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2015 | 5223 | 0.120 |
Why?
|
| Genetic Testing | 3 | 2022 | 3444 | 0.110 |
Why?
|
| Spinal Cord Injuries | 1 | 2001 | 931 | 0.110 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2018 | 627 | 0.110 |
Why?
|
| Albumins | 1 | 1996 | 568 | 0.110 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2014 | 53 | 0.110 |
Why?
|
| Mice | 20 | 2023 | 81201 | 0.110 |
Why?
|
| Logistic Models | 3 | 2015 | 13409 | 0.110 |
Why?
|
| Automobile Driving | 1 | 2018 | 431 | 0.110 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2019 | 3020 | 0.110 |
Why?
|
| Fellowships and Scholarships | 1 | 2021 | 1078 | 0.110 |
Why?
|
| Sequence Analysis, RNA | 1 | 2021 | 2012 | 0.110 |
Why?
|
| Communication | 4 | 2021 | 3750 | 0.110 |
Why?
|
| Turner Syndrome | 1 | 2014 | 130 | 0.110 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2022 | 2540 | 0.110 |
Why?
|
| Transforming Growth Factor beta | 1 | 2021 | 2007 | 0.110 |
Why?
|
| Somatostatin | 1 | 2014 | 459 | 0.110 |
Why?
|
| Laryngeal Diseases | 1 | 2016 | 241 | 0.110 |
Why?
|
| Risk Assessment | 5 | 2015 | 23336 | 0.110 |
Why?
|
| Poxviridae | 1 | 1992 | 37 | 0.110 |
Why?
|
| Immediate-Early Proteins | 1 | 2015 | 453 | 0.110 |
Why?
|
| Age Distribution | 1 | 2018 | 2902 | 0.110 |
Why?
|
| Travel | 1 | 2018 | 788 | 0.110 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2022 | 2282 | 0.110 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2012 | 96 | 0.100 |
Why?
|
| Muscle, Skeletal | 2 | 2021 | 4925 | 0.100 |
Why?
|
| Ambulatory Care Facilities | 1 | 2018 | 934 | 0.100 |
Why?
|
| Diagnostic Imaging | 2 | 2019 | 3508 | 0.100 |
Why?
|
| Rabies | 1 | 1992 | 61 | 0.100 |
Why?
|
| Membrane Transport Proteins | 1 | 1998 | 1031 | 0.100 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2021 | 2455 | 0.100 |
Why?
|
| Pregnancy | 4 | 2015 | 29144 | 0.100 |
Why?
|
| Infratentorial Neoplasms | 1 | 2012 | 94 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2021 | 9955 | 0.100 |
Why?
|
| Principal Component Analysis | 1 | 2015 | 940 | 0.100 |
Why?
|
| Arachnoid | 2 | 2009 | 48 | 0.100 |
Why?
|
| Cell Proliferation | 6 | 2023 | 10483 | 0.100 |
Why?
|
| Adaptation, Psychological | 2 | 2020 | 2575 | 0.100 |
Why?
|
| Radiography | 2 | 2014 | 7023 | 0.100 |
Why?
|
| Emotions | 1 | 2023 | 2659 | 0.100 |
Why?
|
| Loneliness | 1 | 2013 | 185 | 0.100 |
Why?
|
| Urban Population | 1 | 1999 | 2022 | 0.100 |
Why?
|
| Biological Specimen Banks | 1 | 2016 | 711 | 0.100 |
Why?
|
| Live Birth | 1 | 2014 | 512 | 0.100 |
Why?
|
| Review Literature as Topic | 1 | 2013 | 336 | 0.100 |
Why?
|
| Proteinuria | 1 | 2014 | 658 | 0.100 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2018 | 3480 | 0.100 |
Why?
|
| Air Microbiology | 1 | 1991 | 87 | 0.100 |
Why?
|
| Anesthetics, Local | 1 | 1998 | 985 | 0.090 |
Why?
|
| United States | 7 | 2022 | 69872 | 0.090 |
Why?
|
| Morpholines | 3 | 2020 | 571 | 0.090 |
Why?
|
| Genes, tat | 1 | 1990 | 15 | 0.090 |
Why?
|
| Cyclin D1 | 1 | 2012 | 463 | 0.090 |
Why?
|
| Aged, 80 and over | 10 | 2015 | 57776 | 0.090 |
Why?
|
| Orthopedic Procedures | 1 | 2021 | 1289 | 0.090 |
Why?
|
| 3' Untranslated Regions | 1 | 2012 | 513 | 0.090 |
Why?
|
| Psychotherapy | 1 | 2019 | 1642 | 0.090 |
Why?
|
| RNA Stability | 1 | 2012 | 321 | 0.090 |
Why?
|
| Family | 3 | 2016 | 3147 | 0.090 |
Why?
|
| Physicians | 1 | 2008 | 4567 | 0.090 |
Why?
|
| Biopsy, Needle | 1 | 2015 | 1641 | 0.090 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2015 | 1771 | 0.090 |
Why?
|
| Self Report | 2 | 2018 | 3553 | 0.090 |
Why?
|
| Social Adjustment | 1 | 2012 | 631 | 0.090 |
Why?
|
| Cerebrospinal Fluid Shunts | 1 | 1991 | 189 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2018 | 8432 | 0.090 |
Why?
|
| Paranasal Sinuses | 1 | 2012 | 250 | 0.090 |
Why?
|
| Virus Integration | 1 | 1992 | 299 | 0.090 |
Why?
|
| Combined Modality Therapy | 4 | 2010 | 8642 | 0.090 |
Why?
|
| Congresses as Topic | 1 | 2014 | 764 | 0.090 |
Why?
|
| Delphi Technique | 2 | 2024 | 779 | 0.090 |
Why?
|
| Neuropilin-2 | 1 | 2009 | 54 | 0.090 |
Why?
|
| Neurosurgical Procedures | 2 | 2015 | 2002 | 0.090 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 2 | 2010 | 664 | 0.090 |
Why?
|
| Neuropilin-1 | 1 | 2009 | 90 | 0.080 |
Why?
|
| Nursing Methodology Research | 1 | 2008 | 67 | 0.080 |
Why?
|
| Cell Line, Tumor | 7 | 2021 | 16690 | 0.080 |
Why?
|
| Image Processing, Computer-Assisted | 5 | 2022 | 8949 | 0.080 |
Why?
|
| Snake Venoms | 1 | 2008 | 39 | 0.080 |
Why?
|
| DNA, Complementary | 1 | 2012 | 2050 | 0.080 |
Why?
|
| Genes, Viral | 1 | 1990 | 718 | 0.080 |
Why?
|
| Injections, Intraventricular | 3 | 2019 | 231 | 0.080 |
Why?
|
| Residence Characteristics | 1 | 2018 | 2050 | 0.080 |
Why?
|
| RNA, Messenger | 3 | 2001 | 13035 | 0.080 |
Why?
|
| Body Image | 1 | 2013 | 610 | 0.080 |
Why?
|
| Double-Blind Method | 1 | 2022 | 12025 | 0.080 |
Why?
|
| Risk Factors | 6 | 2015 | 72296 | 0.080 |
Why?
|
| Cerebrospinal Fluid | 2 | 2007 | 535 | 0.080 |
Why?
|
| Mutation | 6 | 2021 | 29786 | 0.080 |
Why?
|
| Videotape Recording | 1 | 2009 | 352 | 0.080 |
Why?
|
| Perception | 1 | 2015 | 1198 | 0.080 |
Why?
|
| Facial Paralysis | 1 | 2012 | 338 | 0.080 |
Why?
|
| Geriatric Assessment | 1 | 2015 | 1372 | 0.080 |
Why?
|
| Phthalazines | 1 | 2010 | 363 | 0.080 |
Why?
|
| Signal Transduction | 8 | 2020 | 23404 | 0.080 |
Why?
|
| Lung Neoplasms | 2 | 2015 | 13104 | 0.080 |
Why?
|
| Pyrroles | 1 | 2014 | 1146 | 0.080 |
Why?
|
| MAP Kinase Signaling System | 1 | 2015 | 1525 | 0.080 |
Why?
|
| Colorectal Neoplasms | 1 | 2007 | 6773 | 0.080 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2023 | 4034 | 0.080 |
Why?
|
| Peripheral Nervous System | 1 | 2009 | 150 | 0.080 |
Why?
|
| RNA Splicing | 1 | 2012 | 908 | 0.080 |
Why?
|
| Lymphoma, B-Cell | 1 | 2014 | 931 | 0.080 |
Why?
|
| Intelligence | 1 | 2012 | 920 | 0.080 |
Why?
|
| Joint Diseases | 1 | 2011 | 479 | 0.070 |
Why?
|
| Self Concept | 1 | 2013 | 1025 | 0.070 |
Why?
|
| Epigenesis, Genetic | 1 | 2020 | 3646 | 0.070 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2013 | 489 | 0.070 |
Why?
|
| Phenotype | 5 | 2020 | 16367 | 0.070 |
Why?
|
| Mouth Neoplasms | 1 | 2012 | 601 | 0.070 |
Why?
|
| Protons | 2 | 2023 | 1127 | 0.070 |
Why?
|
| Neoplasm Staging | 3 | 2015 | 11031 | 0.070 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2018 | 2737 | 0.070 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2007 | 114 | 0.070 |
Why?
|
| Nurse's Role | 1 | 2008 | 209 | 0.070 |
Why?
|
| Carbon Isotopes | 1 | 2007 | 467 | 0.070 |
Why?
|
| Lyme Neuroborreliosis | 1 | 2007 | 51 | 0.070 |
Why?
|
| Auditory Threshold | 1 | 2008 | 364 | 0.070 |
Why?
|
| Mice, Inbred Strains | 2 | 2001 | 1828 | 0.070 |
Why?
|
| Lung | 2 | 2016 | 9857 | 0.070 |
Why?
|
| Neoplasm Proteins | 2 | 2017 | 3707 | 0.070 |
Why?
|
| Radiotherapy | 3 | 2018 | 1533 | 0.070 |
Why?
|
| Necrosis | 1 | 2010 | 1643 | 0.070 |
Why?
|
| Cooperative Behavior | 1 | 2013 | 1504 | 0.070 |
Why?
|
| Simian immunodeficiency virus | 1 | 1992 | 846 | 0.070 |
Why?
|
| Peptides, Cyclic | 1 | 2008 | 400 | 0.070 |
Why?
|
| Neoplasms | 3 | 2022 | 21696 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2007 | 437 | 0.070 |
Why?
|
| Microsatellite Repeats | 1 | 2008 | 802 | 0.070 |
Why?
|
| Indoles | 1 | 2014 | 1839 | 0.070 |
Why?
|
| Autopsy | 2 | 2024 | 1020 | 0.070 |
Why?
|
| Genetics, Medical | 1 | 2008 | 338 | 0.070 |
Why?
|
| Infant, Newborn | 5 | 2014 | 25628 | 0.070 |
Why?
|
| Speech Perception | 1 | 2010 | 490 | 0.070 |
Why?
|
| Vestibular Diseases | 1 | 2008 | 217 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2020 | 17446 | 0.070 |
Why?
|
| Borrelia burgdorferi | 1 | 2007 | 180 | 0.060 |
Why?
|
| Maximum Tolerated Dose | 3 | 2015 | 892 | 0.060 |
Why?
|
| Ear, Inner | 1 | 2009 | 420 | 0.060 |
Why?
|
| Scoliosis | 1 | 2011 | 725 | 0.060 |
Why?
|
| Hydrocephalus | 1 | 1991 | 748 | 0.060 |
Why?
|
| Delivery, Obstetric | 1 | 2012 | 906 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 4 | 2018 | 6313 | 0.060 |
Why?
|
| Stereotaxic Techniques | 2 | 2019 | 536 | 0.060 |
Why?
|
| Operating Rooms | 1 | 1991 | 817 | 0.060 |
Why?
|
| Eye | 1 | 2009 | 729 | 0.060 |
Why?
|
| Genomics | 1 | 2020 | 5717 | 0.060 |
Why?
|
| Blindness | 1 | 2009 | 615 | 0.060 |
Why?
|
| Brain | 7 | 2021 | 26388 | 0.060 |
Why?
|
| Paralysis | 3 | 2012 | 247 | 0.060 |
Why?
|
| Heart Neoplasms | 1 | 2007 | 374 | 0.060 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 5321 | 0.060 |
Why?
|
| DNA Methylation | 2 | 2020 | 4285 | 0.060 |
Why?
|
| Autistic Disorder | 2 | 2012 | 1185 | 0.060 |
Why?
|
| Deoxycholic Acid | 1 | 2023 | 54 | 0.060 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2014 | 1378 | 0.060 |
Why?
|
| Molecular Biology | 1 | 2007 | 596 | 0.060 |
Why?
|
| Gene Dosage | 1 | 2008 | 1252 | 0.060 |
Why?
|
| Sexual Behavior | 1 | 2013 | 2055 | 0.060 |
Why?
|
| Cytomegalovirus Infections | 1 | 1990 | 820 | 0.060 |
Why?
|
| Biological Transport | 3 | 1997 | 2120 | 0.060 |
Why?
|
| Research Design | 3 | 2024 | 5984 | 0.060 |
Why?
|
| Vertigo | 1 | 2005 | 202 | 0.060 |
Why?
|
| Regression Analysis | 1 | 2013 | 6459 | 0.060 |
Why?
|
| Sciatic Nerve | 2 | 2017 | 607 | 0.060 |
Why?
|
| Software | 2 | 2017 | 4441 | 0.050 |
Why?
|
| Forecasting | 1 | 2012 | 2951 | 0.050 |
Why?
|
| DNA Modification Methylases | 2 | 2013 | 206 | 0.050 |
Why?
|
| Ataxia | 1 | 2005 | 304 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2019 | 11525 | 0.050 |
Why?
|
| Haplotypes | 1 | 2009 | 2779 | 0.050 |
Why?
|
| Louisiana | 2 | 1999 | 108 | 0.050 |
Why?
|
| Advance Care Planning | 1 | 2009 | 662 | 0.050 |
Why?
|
| Brain Edema | 1 | 2007 | 617 | 0.050 |
Why?
|
| Choroid | 1 | 2024 | 322 | 0.050 |
Why?
|
| Cross Infection | 1 | 1991 | 1417 | 0.050 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2023 | 284 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2010 | 15535 | 0.050 |
Why?
|
| Oxygen | 1 | 2013 | 4189 | 0.050 |
Why?
|
| Surgical Wound Infection | 1 | 1991 | 1540 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2021 | 3554 | 0.050 |
Why?
|
| Piperidines | 1 | 2010 | 1602 | 0.050 |
Why?
|
| RNA, Small Interfering | 2 | 2009 | 3505 | 0.050 |
Why?
|
| Muscle Strength Dynamometer | 1 | 2021 | 43 | 0.050 |
Why?
|
| Cranial Irradiation | 1 | 2004 | 401 | 0.050 |
Why?
|
| Digoxigenin | 1 | 2001 | 26 | 0.050 |
Why?
|
| DNA Repair Enzymes | 2 | 2013 | 349 | 0.050 |
Why?
|
| Child, Preschool | 6 | 2016 | 41005 | 0.050 |
Why?
|
| Chemoprevention | 1 | 2023 | 319 | 0.050 |
Why?
|
| Syndrome | 1 | 2007 | 3252 | 0.050 |
Why?
|
| Alleles | 1 | 2012 | 6933 | 0.050 |
Why?
|
| Diagnosis, Differential | 7 | 2014 | 12961 | 0.050 |
Why?
|
| Sciatic Neuropathy | 1 | 2021 | 74 | 0.050 |
Why?
|
| Receptor, EphA2 | 1 | 2020 | 42 | 0.050 |
Why?
|
| Nerve Regeneration | 2 | 2017 | 788 | 0.050 |
Why?
|
| Age Factors | 2 | 2012 | 18373 | 0.050 |
Why?
|
| Pandemics | 1 | 2021 | 8385 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2015 | 21748 | 0.050 |
Why?
|
| Sleep | 1 | 2016 | 4622 | 0.050 |
Why?
|
| Health Services Needs and Demand | 1 | 2008 | 1410 | 0.050 |
Why?
|
| Aluminum | 1 | 2001 | 152 | 0.050 |
Why?
|
| Radioimmunoassay | 1 | 2001 | 919 | 0.050 |
Why?
|
| Central Nervous System | 2 | 2023 | 1357 | 0.050 |
Why?
|
| Benzoxazoles | 1 | 2020 | 77 | 0.050 |
Why?
|
| Mice, Nude | 2 | 2021 | 3689 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 2 | 2015 | 552 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2012 | 3611 | 0.040 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2021 | 1660 | 0.040 |
Why?
|
| Half-Life | 1 | 2001 | 661 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 3 | 2015 | 6171 | 0.040 |
Why?
|
| Immunoenzyme Techniques | 2 | 2013 | 1799 | 0.040 |
Why?
|
| Rodentia | 1 | 2021 | 261 | 0.040 |
Why?
|
| Glasgow Coma Scale | 1 | 2001 | 570 | 0.040 |
Why?
|
| Cranial Nerve Diseases | 2 | 2012 | 112 | 0.040 |
Why?
|
| Mice, Inbred ICR | 2 | 1997 | 352 | 0.040 |
Why?
|
| Antigens, CD19 | 1 | 2022 | 380 | 0.040 |
Why?
|
| Losartan | 1 | 2021 | 299 | 0.040 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 2019 | 85 | 0.040 |
Why?
|
| Neutralization Tests | 2 | 1992 | 758 | 0.040 |
Why?
|
| Immunoblotting | 2 | 2015 | 1683 | 0.040 |
Why?
|
| Motivation | 1 | 2008 | 1971 | 0.040 |
Why?
|
| Remission Induction | 1 | 2004 | 2385 | 0.040 |
Why?
|
| Triazines | 1 | 2020 | 315 | 0.040 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2020 | 315 | 0.040 |
Why?
|
| Face | 1 | 2005 | 994 | 0.040 |
Why?
|
| Sirolimus | 2 | 2020 | 1565 | 0.040 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2014 | 3658 | 0.040 |
Why?
|
| Macrophages | 1 | 2013 | 5660 | 0.040 |
Why?
|
| Chlorofluorocarbons | 1 | 1998 | 12 | 0.040 |
Why?
|
| Prilocaine | 1 | 1998 | 19 | 0.040 |
Why?
|
| Ointments | 1 | 1998 | 59 | 0.040 |
Why?
|
| Atmosphere | 1 | 1998 | 33 | 0.040 |
Why?
|
| Podiatry | 1 | 1998 | 22 | 0.040 |
Why?
|
| Injections, Intravenous | 3 | 1996 | 1420 | 0.040 |
Why?
|
| Photography | 1 | 2021 | 520 | 0.040 |
Why?
|
| Sex Factors | 1 | 2012 | 10400 | 0.040 |
Why?
|
| Transfection | 3 | 2009 | 5895 | 0.040 |
Why?
|
| Cicatrix | 1 | 2023 | 764 | 0.040 |
Why?
|
| Poverty Areas | 1 | 1999 | 275 | 0.040 |
Why?
|
| Terminal Care | 1 | 2009 | 1694 | 0.040 |
Why?
|
| Herpes Simplex | 2 | 1991 | 470 | 0.040 |
Why?
|
| Gene Fusion | 1 | 2020 | 371 | 0.040 |
Why?
|
| Radiopharmaceuticals | 1 | 2007 | 2645 | 0.040 |
Why?
|
| Mice, Mutant Strains | 1 | 2021 | 1865 | 0.040 |
Why?
|
| Sample Size | 1 | 2021 | 845 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2020 | 2504 | 0.040 |
Why?
|
| Brain Chemistry | 1 | 2001 | 982 | 0.040 |
Why?
|
| Genotype | 2 | 2023 | 12952 | 0.040 |
Why?
|
| Disease Management | 2 | 2019 | 2460 | 0.040 |
Why?
|
| Epilepsy | 1 | 2012 | 3310 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 1 | 2008 | 4805 | 0.040 |
Why?
|
| Luciferases | 1 | 2019 | 733 | 0.040 |
Why?
|
| Vulnerable Populations | 1 | 2022 | 686 | 0.040 |
Why?
|
| Median Eminence | 1 | 1996 | 37 | 0.040 |
Why?
|
| Folic Acid | 1 | 2023 | 1300 | 0.040 |
Why?
|
| Pyridazines | 1 | 2018 | 202 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2021 | 19905 | 0.040 |
Why?
|
| Time Factors | 3 | 2021 | 40075 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2014 | 2649 | 0.030 |
Why?
|
| Species Specificity | 1 | 2000 | 2478 | 0.030 |
Why?
|
| Cerebral Hemorrhage | 1 | 2007 | 2647 | 0.030 |
Why?
|
| Sarcoma | 1 | 2007 | 1897 | 0.030 |
Why?
|
| Research Personnel | 1 | 2021 | 573 | 0.030 |
Why?
|
| Osmolar Concentration | 1 | 1997 | 683 | 0.030 |
Why?
|
| Capital Financing | 1 | 2016 | 58 | 0.030 |
Why?
|
| Rotarod Performance Test | 1 | 2015 | 64 | 0.030 |
Why?
|
| Trust | 1 | 2020 | 505 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2008 | 14723 | 0.030 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2021 | 838 | 0.030 |
Why?
|
| Organ Culture Techniques | 1 | 2018 | 813 | 0.030 |
Why?
|
| Fatal Outcome | 2 | 2012 | 1851 | 0.030 |
Why?
|
| Pineal Gland | 1 | 1996 | 166 | 0.030 |
Why?
|
| Flow Cytometry | 3 | 2013 | 5974 | 0.030 |
Why?
|
| Vestibular Nerve | 1 | 2015 | 101 | 0.030 |
Why?
|
| Iodine Radioisotopes | 2 | 1996 | 1032 | 0.030 |
Why?
|
| Tibia | 1 | 2021 | 1077 | 0.030 |
Why?
|
| Cell Hypoxia | 1 | 2017 | 675 | 0.030 |
Why?
|
| Injections | 1 | 1998 | 840 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 2019 | 1547 | 0.030 |
Why?
|
| Recombinant Proteins | 3 | 2021 | 6621 | 0.030 |
Why?
|
| Lidocaine | 1 | 1998 | 544 | 0.030 |
Why?
|
| Glioma | 1 | 2009 | 3401 | 0.030 |
Why?
|
| Ozone | 1 | 1998 | 469 | 0.030 |
Why?
|
| Cerebral Ventricle Neoplasms | 1 | 2014 | 44 | 0.030 |
Why?
|
| Systems Biology | 1 | 2018 | 469 | 0.030 |
Why?
|
| Patients | 1 | 2021 | 900 | 0.030 |
Why?
|
| Receptors, Cytokine | 1 | 1995 | 262 | 0.030 |
Why?
|
| DNA, Viral | 2 | 1992 | 2227 | 0.030 |
Why?
|
| Factor Analysis, Statistical | 1 | 2017 | 977 | 0.030 |
Why?
|
| Receptors, Interleukin-1 | 1 | 1995 | 262 | 0.030 |
Why?
|
| Receptors, Somatostatin | 1 | 2014 | 129 | 0.030 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2019 | 602 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2019 | 8319 | 0.030 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2015 | 876 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2014 | 20130 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2008 | 3922 | 0.030 |
Why?
|
| Hypertension | 1 | 2014 | 8479 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2021 | 3914 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2018 | 1879 | 0.030 |
Why?
|
| Pediatrics | 1 | 2008 | 3475 | 0.030 |
Why?
|
| Antigens, CD | 2 | 2013 | 4026 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2013 | 3873 | 0.030 |
Why?
|
| Lateral Ventricles | 1 | 2014 | 147 | 0.030 |
Why?
|
| Radiation Tolerance | 1 | 2015 | 486 | 0.030 |
Why?
|
| Quinolines | 1 | 2018 | 732 | 0.030 |
Why?
|
| Antibodies, Viral | 2 | 1996 | 3177 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2013 | 2850 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2018 | 2716 | 0.030 |
Why?
|
| Canaries | 1 | 1992 | 6 | 0.030 |
Why?
|
| Demography | 1 | 2017 | 1655 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2014 | 6539 | 0.030 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2013 | 200 | 0.030 |
Why?
|
| Immunization | 1 | 1997 | 1256 | 0.030 |
Why?
|
| Hypothermia, Induced | 1 | 1998 | 752 | 0.030 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 1995 | 595 | 0.030 |
Why?
|
| Muscular Atrophy | 1 | 2015 | 347 | 0.030 |
Why?
|
| HIV-1 | 1 | 1990 | 6939 | 0.030 |
Why?
|
| Community Health Services | 1 | 1997 | 650 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 1782 | 0.030 |
Why?
|
| Patient Participation | 1 | 2021 | 1457 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2023 | 3778 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2020 | 2682 | 0.030 |
Why?
|
| Vincristine | 1 | 2014 | 1039 | 0.030 |
Why?
|
| Minority Groups | 1 | 1999 | 1221 | 0.030 |
Why?
|
| Tissue Transplantation | 1 | 2012 | 130 | 0.030 |
Why?
|
| Skull Neoplasms | 1 | 2012 | 173 | 0.020 |
Why?
|
| Surgical Equipment | 1 | 1991 | 57 | 0.020 |
Why?
|
| Edema | 1 | 2015 | 789 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2016 | 1677 | 0.020 |
Why?
|
| Heterozygote | 1 | 2017 | 2804 | 0.020 |
Why?
|
| Colony Count, Microbial | 1 | 1991 | 331 | 0.020 |
Why?
|
| User-Computer Interface | 1 | 2017 | 1431 | 0.020 |
Why?
|
| Thorax | 1 | 2014 | 547 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2014 | 693 | 0.020 |
Why?
|
| Educational Measurement | 1 | 2017 | 1210 | 0.020 |
Why?
|
| Bone Density | 1 | 2023 | 3468 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2015 | 1656 | 0.020 |
Why?
|
| Peritoneum | 1 | 1991 | 228 | 0.020 |
Why?
|
| Jugular Veins | 1 | 1991 | 204 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2020 | 1972 | 0.020 |
Why?
|
| Acyclovir | 1 | 1991 | 272 | 0.020 |
Why?
|
| Drug Discovery | 1 | 2018 | 1058 | 0.020 |
Why?
|
| Laryngoscopy | 1 | 2016 | 710 | 0.020 |
Why?
|
| Receptor, TIE-2 | 1 | 2010 | 178 | 0.020 |
Why?
|
| Data Collection | 1 | 1999 | 3339 | 0.020 |
Why?
|
| Antibodies | 2 | 2015 | 2460 | 0.020 |
Why?
|
| Infant | 4 | 2015 | 35134 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2019 | 2419 | 0.020 |
Why?
|
| Mice, Knockout | 2 | 2019 | 14561 | 0.020 |
Why?
|
| Vidarabine | 1 | 1991 | 345 | 0.020 |
Why?
|
| Base Sequence | 2 | 1992 | 12797 | 0.020 |
Why?
|
| Corpus Callosum | 1 | 2014 | 737 | 0.020 |
Why?
|
| Opportunistic Infections | 1 | 2012 | 389 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2000 | 8300 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2010 | 399 | 0.020 |
Why?
|
| Prevalence | 2 | 2011 | 15221 | 0.020 |
Why?
|
| Prednisone | 1 | 2014 | 1574 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2015 | 15160 | 0.020 |
Why?
|
| Fibroblasts | 2 | 2009 | 4162 | 0.020 |
Why?
|
| Enterovirus Infections | 1 | 1989 | 72 | 0.020 |
Why?
|
| Cerebellum | 1 | 1996 | 1488 | 0.020 |
Why?
|
| Cells, Cultured | 3 | 2009 | 19233 | 0.020 |
Why?
|
| Endpoint Determination | 1 | 2011 | 601 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2018 | 1940 | 0.020 |
Why?
|
| Cross-Sectional Studies | 2 | 2022 | 25039 | 0.020 |
Why?
|
| Cell Movement | 1 | 2020 | 5218 | 0.020 |
Why?
|
| Microscopy, Electron | 1 | 2012 | 2646 | 0.020 |
Why?
|
| Guinea Pigs | 1 | 1990 | 1386 | 0.020 |
Why?
|
| Chick Embryo | 1 | 1990 | 982 | 0.020 |
Why?
|
| Cell Survival | 1 | 2018 | 5882 | 0.020 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1990 | 798 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2014 | 2242 | 0.020 |
Why?
|
| DNA Damage | 1 | 2018 | 2432 | 0.020 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 1990 | 442 | 0.020 |
Why?
|
| Catenins | 1 | 2007 | 41 | 0.020 |
Why?
|
| Molecular Sequence Data | 2 | 1992 | 18111 | 0.020 |
Why?
|
| Standard of Care | 1 | 2011 | 564 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2013 | 2887 | 0.020 |
Why?
|
| Health Personnel | 1 | 2021 | 3219 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1990 | 1801 | 0.020 |
Why?
|
| Radiography, Thoracic | 1 | 2014 | 1265 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2014 | 2234 | 0.020 |
Why?
|
| Bromodeoxyuridine | 1 | 2007 | 322 | 0.020 |
Why?
|
| Nervous System Diseases | 1 | 2017 | 1622 | 0.020 |
Why?
|
| Incidental Findings | 1 | 2011 | 689 | 0.020 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2014 | 2016 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2022 | 3749 | 0.020 |
Why?
|
| Plasmids | 1 | 1992 | 2308 | 0.020 |
Why?
|
| Drug Delivery Systems | 1 | 1998 | 2219 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2023 | 10183 | 0.020 |
Why?
|
| Physician-Patient Relations | 1 | 1999 | 3229 | 0.020 |
Why?
|
| Gene Expression | 1 | 2019 | 7798 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2017 | 13814 | 0.020 |
Why?
|
| Contrast Media | 1 | 2018 | 5300 | 0.020 |
Why?
|
| Antibody Formation | 1 | 1990 | 1402 | 0.020 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2009 | 692 | 0.020 |
Why?
|
| Chemokines, CXC | 1 | 2007 | 422 | 0.020 |
Why?
|
| Coronary Aneurysm | 1 | 2007 | 237 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 1996 | 5524 | 0.020 |
Why?
|
| Chemokine CXCL12 | 1 | 2007 | 465 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2017 | 6194 | 0.010 |
Why?
|
| Students, Medical | 1 | 1997 | 1862 | 0.010 |
Why?
|
| Rats | 1 | 2000 | 24252 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 1996 | 4561 | 0.010 |
Why?
|
| Patient-Centered Care | 1 | 2014 | 1438 | 0.010 |
Why?
|
| Kinetics | 1 | 1992 | 6476 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 1990 | 1607 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2017 | 7785 | 0.010 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2015 | 3595 | 0.010 |
Why?
|
| Hyperlipidemias | 1 | 2007 | 789 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 1992 | 3424 | 0.010 |
Why?
|
| Patient Preference | 1 | 2009 | 889 | 0.010 |
Why?
|
| Cytoskeleton | 1 | 2007 | 1185 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2013 | 2917 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 12073 | 0.010 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2012 | 6036 | 0.010 |
Why?
|
| Apoptosis | 1 | 2018 | 9724 | 0.010 |
Why?
|
| Membrane Proteins | 2 | 2010 | 7882 | 0.010 |
Why?
|
| Virus Replication | 1 | 1990 | 2535 | 0.010 |
Why?
|
| Lymphocytes | 1 | 1990 | 2617 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2012 | 4851 | 0.010 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2009 | 980 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2013 | 5867 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2016 | 7730 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2014 | 4153 | 0.010 |
Why?
|
| Antibodies, Bacterial | 1 | 2007 | 1470 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 1990 | 6386 | 0.010 |
Why?
|
| Registries | 1 | 2016 | 8091 | 0.010 |
Why?
|
| Fibroblast Growth Factors | 1 | 2007 | 878 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2009 | 2967 | 0.010 |
Why?
|
| Anticonvulsants | 1 | 2010 | 1916 | 0.010 |
Why?
|
| Bacteria | 1 | 1991 | 2115 | 0.010 |
Why?
|
| Disease Outbreaks | 1 | 1989 | 1771 | 0.010 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2007 | 934 | 0.010 |
Why?
|
| Cerebral Cortex | 1 | 1996 | 5709 | 0.010 |
Why?
|
| Cognition Disorders | 1 | 2014 | 4043 | 0.010 |
Why?
|
| Actins | 1 | 2007 | 2121 | 0.010 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2009 | 2938 | 0.010 |
Why?
|
| Thrombocytopenia | 1 | 2007 | 1178 | 0.010 |
Why?
|
| Neoplastic Stem Cells | 1 | 2007 | 1376 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2013 | 5856 | 0.010 |
Why?
|
| Survival Analysis | 2 | 2007 | 10252 | 0.010 |
Why?
|
| Lumbar Vertebrae | 1 | 2007 | 1848 | 0.010 |
Why?
|
| Encephalitis | 2 | 1991 | 425 | 0.010 |
Why?
|
| Comorbidity | 1 | 2011 | 10388 | 0.010 |
Why?
|
| Decision Making | 1 | 2009 | 3888 | 0.010 |
Why?
|
| Medically Underserved Area | 1 | 1997 | 253 | 0.010 |
Why?
|
| Echocardiography | 1 | 2007 | 5099 | 0.010 |
Why?
|
| Cell Line | 1 | 2009 | 16000 | 0.010 |
Why?
|
| Palliative Care | 1 | 2009 | 3493 | 0.010 |
Why?
|
| Endothelial Cells | 1 | 2007 | 3486 | 0.010 |
Why?
|
| Proteins | 1 | 2009 | 6100 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 2007 | 4666 | 0.010 |
Why?
|
| Solubility | 1 | 1995 | 1088 | 0.010 |
Why?
|
| Permeability | 1 | 1995 | 738 | 0.010 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 1995 | 357 | 0.010 |
Why?
|
| Serum Albumin | 1 | 1995 | 675 | 0.010 |
Why?
|
| Dihydroxyphenylalanine | 1 | 1971 | 76 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2010 | 15520 | 0.010 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 1991 | 188 | 0.010 |
Why?
|
| Philadelphia | 1 | 1989 | 267 | 0.010 |
Why?
|
| Serotonin | 1 | 1971 | 1017 | 0.000 |
Why?
|
| Neurologic Examination | 1 | 1989 | 931 | 0.000 |
Why?
|
| Consciousness | 1 | 1991 | 572 | 0.000 |
Why?
|
| Vaccination | 1 | 1997 | 3279 | 0.000 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1995 | 4424 | 0.000 |
Why?
|
| Spinal Cord | 1 | 1989 | 1810 | 0.000 |
Why?
|
| Recurrence | 1 | 1991 | 8340 | 0.000 |
Why?
|
| Multivariate Analysis | 1 | 1991 | 12244 | 0.000 |
Why?
|
| Hydroxyindoleacetic Acid | 1 | 1971 | 90 | 0.000 |
Why?
|
| Blood Cell Count | 1 | 1971 | 403 | 0.000 |
Why?
|
| Follicle Stimulating Hormone | 1 | 1971 | 744 | 0.000 |
Why?
|
| Luteinizing Hormone | 1 | 1971 | 869 | 0.000 |
Why?
|
| Sleep, REM | 1 | 1971 | 595 | 0.000 |
Why?
|
| Placebos | 1 | 1971 | 1676 | 0.000 |
Why?
|
| Motor Activity | 1 | 1971 | 2715 | 0.000 |
Why?
|
| Blood Platelets | 1 | 1971 | 2509 | 0.000 |
Why?
|